亚宝药业：以4902.35万元转让健民资本份额

Core Viewpoint - The company is optimizing its external investments and improving asset operation efficiency through the transfer of its stake in Wuhan Jianmin Capital Partnership [1] Group 1 - The company announced the transfer of its 50 million yuan stake in Wuhan Jianmin Capital Partnership for 49.0235 million yuan to its wholly-owned subsidiary, Yabao Ailegao Biopharmaceutical Co., Ltd [1] - The company agreed to withdraw from a 70 million yuan stake for 68.633 million yuan [1] - After the transaction, the total capital contribution of all partners in Jianmin Capital will decrease to 205 million yuan, and the company will hold a 24.44% stake in Jianmin Capital through its subsidiary [1]